The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
Open accessAbstract
Eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product halichondrin B and an inhibitor of microtubule dynamics. Some tubulin‐binding drugs are known to have antivascular (antiangiogenesis or vascular‐disrupting) activities that can target abnormal tumor vessels. Using dynamic contrast‐enhanced MRI analyses, here we show that eribulin induces remodeling of tumor vasculature through a novel antivascular activity in MX‐1 and MDA‐MB‐231 human breast cancer xenograft models. Vascular remodeling associated with improved perfusion was shown by Hoechst 33342 staining and by increased microvessel density together with decreased mean vascular areas and fewer branched vessels in tumor tissues, as determined by immunohistochemical staining for endothelial marker CD 31. Quantitative RT‐PCR analysis of normal host cells in the stroma of xenograft tumors showed that eribulin altered the expression of mouse (host) genes in angiogenesis signaling pathways controlling endothelial cell–pericyte interactions, and in the epithelial–mesenchymal transition pathway in the context of the tumor microenvironment. Eribulin also decreased hypoxia‐associated protein expression of mouse (host) vascular endothelial growth factor by ELISA and human CA 9 by immunohistochemical analysis. Prior treatment with eribulin enhanced the anti‐tumor activity of capecitabine in the MDA‐MB‐231 xenograft model. These findings suggest that eribulin‐induced remodeling of abnormal tumor vasculature leads to a more functional microenvironment that may reduce the aggressiveness of tumors due to elimination of inner tumor hypoxia. Because abnormal tumor microenvironments enhance both drug resistance and metastasis, the apparent ability of eribulin to reverse these aggressive characteristics may contribute to its clinical benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
Tofts, P. S., Brix, G., Buckley, D. L., Evelhoch, J. L., Henderson, E., Knopp, M. V., Larsson, H. B. W., Lee, T.-Y., Mayr, N. A., Parker, G. J. M., et al. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3<223::aid-jmri2>3.0.co;2-s · Cited by 3,143
Microtubule-binding agents: a dynamic field of cancer therapeutics
Dumontet, C., & Jordan, M. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3253 · Cited by 1,718
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Wykoff, C. C., Beasley, N. J. P., Watson, P. H., Turner, K., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K., Maxwell, P. H., et al. (2000) · PubMed · Cited by 1,491
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Disrupting tumour blood vessels
Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1628 · Cited by 930
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., & Taraboletti, G. (1996) · PubMed · Cited by 643
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
Jordan, M. A., Kamath, K., Manna, T., Okouneva, T., Miller, H. P., Davis, C., Littlefield, B. A., & Wilson, L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0345 · Cited by 489
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
O'Connor, J. P. B., Jackson, A., Parker, G. J. M., & Jayson, G. C. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603515 · Cited by 484
Towle, M. J., Salvato, K. A., Budrow, J., Wels, B. F., Kuznetsov, G., Aalfs, K. K., Welsh, S., Zheng, W., Seletsky, B. M., Palme, M. H., et al. (2001) · PubMed · Cited by 483
Rapid calculation of T1 using variable flip angle gradient refocused imaging
Fram, E. K., Herfkens, R. J., Johnson, G. A., Glover, G. H., Karis, J. P., Shimakawa, A., Perkins, T. G., & Pelc, N. J. (1987) · Magnetic Resonance Imaging · doi:10.1016/0730-725x(87)90021-x · Cited by 388
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
O'Connor, J. P. B., Jackson, A., Parker, G. J. M., Roberts, C., & Jayson, G. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.2 · Cited by 348
Tozer, G. M., Prise, V. E., Wilson, J., Čemažar, M., Shan, S., Dewhirst, M. W., Barber, P. R., Vojnovic, B., & Chaplin, D. J. (2001) · PubMed · Cited by 283
Vascular disrupting agents in clinical development
Hinnen, P., & Eskens, F. A. L. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603694 · Cited by 263
Kuznetsov, G., Towle, M. J., Cheng, H., Kawamura, T., TenDyke, K., Liu, D., Kishi, Y., Yu, M. J., & Littlefield, B. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1169 · Cited by 262
Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment
Casazza, A., Di Conza, G., Wenes, M., Finisguerra, V, Deschoemaeker, S., & Mazzone, M. (2014) · Oncogene · doi:10.1038/onc.2013.121 · Cited by 243
Konerding, M. A., Malkusch, W., Klapthor, B., Ackern, C. V., Fait, E., Hill, S. A., Parkins, C., Chaplin, D. J., Presta, M., & Denekamp, J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690416 · Cited by 221
Liao, G., Nagasaki, T., & Gundersen, G. G. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.11.3473 · Cited by 221
Antivascular Actions of Microtubule-Binding Drugs
Schwartz, E. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2710 · Cited by 218
Sevick, E., & Jain, R. K. (1989) · PubMed · Cited by 175
Towle, M. J., Salvato, K. A., Wels, B. F., Aalfs, K. K., Zheng, W., Seletsky, B. M., Zhu, X., Lewis, B. M., Kishi, Y., Yu, M. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1874 · Cited by 141
Pasquier, E., Honoré, S., Pourroy, B., Jordan, M. A., Lehmann, M., Briand, C. M., & Braguer, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2624 · Cited by 138
Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor Vascularity
Salmon, H. W., & Siemann, D. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0163 · Cited by 108
Patterson, D. M., Zweifel, M., Middleton, M. R., Price, P., Folkes, L. K., Stratford, M. R. L., Ross, P., Halford, S. E. R., Peters, J., Balkissoon, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2414 · Cited by 76
Donoghue, M. B., Lemery, S. J., Yuan, W., He, K., Sridhara, R., Shord, S. S., Zhao, H., Marathe, A., Kotch, L. E., Jee, J. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2149 · Cited by 45
Péan, E., Klaar, S., Berglund, E. G., Salmonson, T., Borregaard, J., Hofland, K. F., Ersbøll, J., Abadie, E., Giuliani, R., & Pignatti, F. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3075 · Cited by 39
Cited by
EMT, cell plasticity and metastasis
Chaffer, C. L., San Juan, B. P., Lim, E., & Weinberg, R. A. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9648-7 · Cited by 861
Schöffski, P., Chawla, S., Maki, R. G., Italiano, A., Gelderblom, H., Choy, E., Grignani, G., Camargo, V., Bauer, S., Rha, S. Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01283-0 · Cited by 778
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Microtubule-targeting agents and their impact on cancer treatment
Čermák, V., Dostál, V., Jelínek, M., Libusová, L., Kovář, J., Rösel, D., & Brábek, J. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151075 · Cited by 275
Metadata
- Authors
- Funahashi, Y., Okamoto, K., Adachi, Y., Semba, T., Uesugi, M., Ozawa, Y., Tohyama, O., Uehara, T., Kimura, T., Watanabe, H., Asano, M., Kawano, S., Tizon, X., McCracken, P. J., Matsui, J., Aoshima, K., Nomoto, K., & Oda, Y.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2014-09-16
- Volume
- 105
- Issue
- 10
- Pages
- 1334-1342
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W1983225377
- Cited by
- 277
- References
- 33
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.